Cell Therapy News 19.22 June 25, 2018 | |
| |
TOP STORYScientists compared the function of clinical-grade human parthenogenetic embryonic stem cell (ESC)-derived midbrain dopaminergic neurons in two canonical protocols in a primate Parkinson’s disease model. [Stem Cell Reports] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers validated the feasibility and efficacy of intratumoral radiofrequency hyperthermia-enhanced herpes simplex virus thymidine kinase and ganciclovir gene therapy for non-small-cell lung cancer. [Radiology] Abstract The authors provided new mechanistic evidence for a role of miR-210 in proangiogenic cells (PACs). In vivo, migration toward and adhesion to the ischemic endothelium facilitated the proangiogenic actions of transplanted PACs. [Mol Ther] Abstract Investigators hypothesized that B cell alterations in bone marrow account for the reduced therapeutic potential of post-myocardial infarction (MI) and aged donor bone marrow cells (BMCs). Injection of BMCs from increasingly aged donor mice resulted in progressively poorer cardiac function and larger infarct size. [Mol Ther] Abstract mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo Scientists demonstrated that the selection of the appropriate end-oligopeptide modifications enabled the specific targeting and major transfection of antigen-presenting cells in vivo, after intravenous administration, thus enabling their use for immunotherapy strategies. [Adv Healthc Mater] Abstract Researchers identified a feasible and reproducible method to instantly produce a fibrin glue-mesenchymal stromal cell (MSC) complex directly on the heart surface. This complex exhibited prompt, firm adhesion to the heart, markedly improving initial retention of donor MSCs compared to intramyocardial injection. [Sci Rep] Full Article Treatment of murine oral cancer 2 tumor-bearing wild-type C57BL/6 mice with AZD1775 and adoptively transferred KIL cells resulted in enhanced tumor growth control and survival over controls or either treatment alone. [J Immunother Cancer] Full Article Arginase I mRNA Therapy – A Novel Approach to Rescue Arginase 1 Enzyme Deficiency Investigators demonstrated in vitro and in vivo that administration of arginase I (ARG1) mRNA increased ARG1 protein expression and specific activity in relevant cell types, including ARG1-deficient patient cell lines, as well as in wild type mice for up to four days. [RNA Biol] Abstract In vivo, erythropoietin (EPO)-bone mesenchymal stem cells (BMSCs) showed higher ability to improve renal function than BMSCs, and in cyclosporine A-induced rats treated with EPO-BMSCs, interstitial lymphocyte infiltration, tubular swelling, necrosis, and interstitial fibrosis decreased. [J Cell Biochem] Abstract Subscribe to one of our other 19 science newsletters such as Mesenchymal Cell News & ESC & iPSC News. | |
| |
REVIEWSA Mechanistic Roadmap for the Clinical Application of Cardiac Cell Therapies The author provides an overview of recent cardiac cell therapies, with a focus on the hurdles limiting the translation of cell products from research laboratories to clinical practice. [Nat Biomed Eng] Abstract Recent Advances and Future of Gene Therapy for Bone Regeneration Investigators discuss the recent advances in gene therapy as a treatment for bone regeneration. While most fractures heal spontaneously, patients who present with fracture nonunion suffer from prolonged pain, disability, and often require additional operations to regain musculoskeletal function. [Curr Osteoporos Rep] Abstract Visit our reviews page to see a complete list of reviews in the cell therapy research field. | |
| |
SCIENCE NEWSKey Day 100 Survival Outcomes of Phase III Trial for Acute Graft versus Host Disease Presented Mesoblast Limited announced key day 100 survival outcomes of its Phase III trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in children with steroid refractory acute graft versus host disease. [Press release from Mesoblast Limited discussing research presented at the 2018 International Society for Stem Cell Research (ISSCR) Annual Meeting, Melbourne] Download Press Release First In Vivo Proof-of-Concept Data with CD8+ CAR-Treg Presented TxCell SA announced that Dr Carole Guillonneau, PhD, will present proof-of-concept preclinical data, generated by TxCell and CRTI. The oral presentation is entitled “Cell therapy with engineered HLA-A2 specific CAR-CD8+ Tregs to avoid transplant rejection“. [Press release from TxCell SA discussing research presented at the Federation of Clinical Immunology Societies (FOCIS 2018), San Francisco] Press Release | |
| |
INDUSTRY NEWSAbbVie and Calibr Announce Collaboration for Next Generation T-Cell Therapies AbbVie and Calibr announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. [AbbVie Inc.] Press Release U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries Pluristem Therapeutics Inc. announced it has entered into an additional collaboration agreement with the U.S. Department of Defense and its United States Army Medical Research Institute of Chemical Defense to study the company’s PLX-R18 cell therapy product in the treatment of long term lung injuries following exposure to mustard gas. [Pluristem Therapeutics Inc.] Press Release Pluristem Therapeutics Inc. reported positive data from studies conducted in collaboration with Fukushima Medical University evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal tract and bone marrow. [Pluristem Therapeutics Inc.] Press Release BrainStorm to Host a Conference Call to Announce Its “Right To Try” Policy BrainStorm Cell Therapeutics Inc. will hold a conference call to announce its policy in regards to the “Right To Try” legislation. [BrainStorm Cell Therapeutics Inc.] Press Release Caladrius Biosciences, Inc. announced that the FDA has granted regenerative medicine advanced therapy designation to the company’s late-stage CD34+ cell therapy program for the treatment of refractory angina. [Caladrius Biosciences, Inc.] Press Release Penn State Cancer Institute Now Offering CAR T-Cell Therapy The Penn State Cancer Institute is now the first and only oncology center in central Pennsylvania to offer patients CAR T-cell therapy, a cutting-edge treatment that has been successful in treating a common type of lymphoma. [The Penn State Cancer Institute] Press Release Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass. Mustang Bio, Inc. announced that it has opened a CAR T cell therapy manufacturing facility at UMass Medicine Science Park in Worcester, Mass. [Mustang Bio, Inc.] Press Release Sarepta Therapeutics, Inc. announced that at the company’s R&D Day, Jerry Mendell, M.D. of Nationwide Children’s Hospital presented positive preliminary results from its Phase I/IIa gene therapy clinical trial assessing AAVrh74.MHCK7.micro-Dystrophin in individuals with Duchenne muscular dystrophy. [Sarepta Therapeutics, Inc.] Press Release Seattle Children’s has opened a pioneering chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory HER2-positive central nervous system tumors where CAR T cells will be delivered directly into the brain. [Seattle Children’s Hospital] Press Release Cynata Reports Positive 28-Day Data from Cohort B of Phase I Trial of CYP-001 in GvHD Cynata Therapeutics Limited announced positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase I clinical trial of CYP-001, the company’s lead Cymerus™ mesenchymal stem cell product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Cynata Therapeutics Limited (GlobeNewswire, Inc.)] Press Release | |
| |
POLICY NEWSWhite House Proposes a Narrowing of FDA’s Mission — And a New Name The Trump administration has proposed a fundamental change to the mission of the FDA, one that would transfer most of the responsibility for regulating food safety to the Department of Agriculture and rename the FDA the “Federal Drug Administration.” [STAT News] Editorial US-Chinese Trade War Puts Scientists in the Cross Hairs Scientific research in the United States could become collateral damage in the country’s escalating trade dispute with China. Both countries went head-to-head in mid-June over tariffs on a long list of goods that includes lab equipment and reagents. That is likely to increase the cost of scientific research, and the impact could be felt more keenly in US labs. [Nature News] Editorial African Scientists Launch Their Own Preprint A group of open science advocates have launched the first preprint aimed exclusively at African scientists. AfricArxiv seeks to improve the visibility of African science by helping academics share their work quickly, say co-founders Justin Ahinon, and Jo Havemann. [Nature News] Editorial
| |
REGULATORYNIHProspective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer (FR Doc. No:2018-13486) Notice
| |
EVENTSNEW International Society for Cellular Therapy (ISCT) EU 2018 Regional Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Project Leader – Gene and Cellular Therapy (CELLECTIS Inc.) NEW Postdoctoral Position – Corneal Diseases (University of California, Los Angeles) PhD Student – Cellular Immunotherapy (Glycostem Therapeutics) Research Associate/PhD Position – iPS Cell-Derived Neurons to Model Parkinson’s Disease (TU Dresden) Postdoctoral Fellow – Gene Editing and Cellular Reprogramming (Houston Methodist Research Institute) Faculty Position – Adoptive T Cell Therapy (Dana-Farber Cancer Institute) Group Manager – AAV Vector Expression Systems (Genethon) Scientist/Senior Scientist – Lentivirus Production (Obsidian Therapeutics) Scientist/Senior Scientist – Bioinformatics and Data Sciences (Obsidian Therapeutics) Postdoctoral Fellow – Immunology, Immunotherapy, Gene Therapy (City of Hope) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cell Therapy News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|